Australia's LTR Pharma hits record high on partnership for nasal spray

Ltr Pharma

13/08/2024 03:56

** Shares of LTR Pharma  LTP.AX  soar as much as 29.5% to a
record high of A$1.250
    ** Biopharmaceutical co signs co-development agreement with
Aptar Pharma for SPONTAN nasal spray for global markets
    ** Primary goal is commercialisation of SPONTAN in the
United States and other key markets - co
    ** Says partnership with Aptar Pharma will be beneficial in
obtaining U.S. Food and Drug Administration (FDA) approval for
SPONTAN
    ** Stock posts its biggest intraday pct gain since June 7
    ** About 2.3 mln shares change hands, compared with the
30-day average volume of 600,999
    ** Stock up 179.7% this year, as of last close

 (Reporting by Rajasik Mukherjee in Bengaluru)
 ((Rajasik.Mukherjee@thomsonreuters.com;))